BriaCell Therapeutics Income Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021
Selling, General & Admin	5.61	5.93	6.15	7.94	7.27	4.96
Research & Development	22.73	21.27	27.18	15.34	8.02	2.02
Total Operating Expenses	28.34	27.2	33.33	23.27	15.29	6.98
Operating Income	-28.34	-27.2	-33.33	-23.27	-15.29	-6.98
Other Non-Operating Income (Expense)	0.44	0.34	0.37	0.85	-11.55	-6.84
Total Non-Operating Income (Expense)	0.44	0.34	0.37	0.85	-11.55	-6.84
Pretax Income	-27.9	-26.87	-32.96	-22.42	-26.84	-13.82
Net Income	-27.54	-26.31	-4.79	-20.3	-26.84	-13.82
Minority Interest in Earnings	0.3	0.24	0.14	-	-	-
Net Income to Common	-27.54	-26.31	-4.79	-20.3	-26.84	-13.82
Shares Outstanding (Basic)	1	0	0	0	0	0
Shares Outstanding (Diluted)	1	0	0	0	0	0
Shares Change (YoY)	781.80%	285.70%	5.35%	0.81%	242.82%	533.09%
EPS (Basic)	-18.52	-62.19	-43.68	-195.00	-259.50	-459.00
EPS (Diluted)	-18.52	-62.19	-43.68	-195.00	-259.50	-459.00
Shares Outstanding	7.25	1.88	0.12	0.11	0.1	0.1
Free Cash Flow	-26.8	-28.17	-24.58	-23.74	-12.48	-7.75
Free Cash Flow Per Share	-18.06	-66.58	-224.09	-228.03	-120.86	-257.22
EBITDA	-28.23	-27.1	-33.25	-23.26	-15.27	-6.96
EBIT	-28.34	-27.2	-33.33	-23.27	-15.29	-6.98

Updated Mar 10, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q